These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32001089)

  • 1. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.
    Shah RR; Redmond JM; Mihut A; Menon M; Evans JP; Murphy JA; Bartholomew MA; Coe DM
    Bioorg Med Chem; 2020 Mar; 28(5):115326. PubMed ID: 32001089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
    Kato JY; Korenaga S; Iwakura M
    Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
    Zhang X; Wang W; Dong G; Song Y; Zhai X; Sheng C
    Bioorg Med Chem Lett; 2024 Sep; 109():129838. PubMed ID: 38838918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
    Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
    Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
    Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
    J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ligase ligand optimization of Clinical PROTACs.
    Jiang H; Xiong H; Gu SX; Wang M
    Front Chem; 2023; 11():1098331. PubMed ID: 36733714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
    Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
    Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
    Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
    Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
    Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
    Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 18. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    Wang C; Zhang Y; Wang J; Xing D
    Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.